Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-14

Study Completion Date

2020-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

NCT04351191

Sars-CoV2 Symptomatic Condition Covid-19

TERMINATED PHASE4

Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19

NCT04359537

COVID 19

UNKNOWN PHASE2

Effectiveness of Hydroxychloroquine in Covid-19 Patients

NCT04328272

COVID19

UNKNOWN PHASE3

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

NCT04341727

Coronavirus Infection

TERMINATED PHASE3

Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19

NCT04362332

COVID-19

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Coronavirus Infection Asymptomatic Condition COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care

Group Type ACTIVE_COMPARATOR

Hydroxychloroquine Sulfate Regular dose

Intervention Type DRUG

Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

Arm 2

Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care

Group Type EXPERIMENTAL

Hydroxychloroquine Sulfate Loading Dose

Intervention Type DRUG

Hydroxychloroquine administered as a loading dose only

Arm 3

Chloroquine 500 mg BID for 5 days plus standard of care

Group Type ACTIVE_COMPARATOR

Chloroquine

Intervention Type DRUG

Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

Arm 4

Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Standard of Care plus placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydroxychloroquine Sulfate Regular dose

Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

Intervention Type DRUG

Hydroxychloroquine Sulfate Loading Dose

Hydroxychloroquine administered as a loading dose only

Intervention Type DRUG

Chloroquine

Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

Intervention Type DRUG

Placebo

Standard of Care plus placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Nasopharyngeal RT-PCR positive SARS-CoV-2 patient
2. Age 20-50 years
3. BMI 18-28 kg/m2
4. Informed consent

Exclusion Criteria

1. Symptoms: Cough, fever, shortness of breath
2. O2 saturation by pulse-oximeter below 94%
3. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes
4. Arrhythmias and/or history of arrythmia
5. Psoriasis and/or history of psoriasis
6. Neuropathy or myopathy and/or history of these
7. Hypoglycemia and/or history of hypoglycemia
8. Pre-existing hepatic disease
9. Pre-existing renal disease
10. Use of antacids within 1 week
11. Use of antibiotics within 1 week
12. Pregnancy
13. RT-PCR performed \>3 days prior to enrollment

Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No